6.3 Endocrine & Hormonal Therapies in Oncology

4.3 Endocrine & Hormonal Therapies in Oncology

Endocrine therapies form a cornerstone of systemic treatment for hormone-dependent malignancies, most notably hormone receptor-positive (HR+) breast cancer and prostate adenocarcinoma. These tumors rely on endogenous steroid hormones—estrogens and androgens, respectively—to stimulate cell proliferation and inhibit apoptosis. Endocrine manipulation aims to deprive tumor cells of hormonal ligands or directly inhibit steroid hormone receptor signal transduction. For the Advanced Oncology Certified Nurse Practitioner (AOCNP®), a thorough understanding of endocrine drug mechanisms, ovarian function suppression protocols, androgen pathway blockade, and long-term toxicity management is vital.

---

1. Estrogen Pathway Interventions in Breast Cancer

Approximately 75% to 80% of invasive breast cancers express the estrogen receptor (ER) and/or progesterone receptor (PR). Endocrine modalities in breast cancer fall into three primary mechanistic categories:

A. Selective Estrogen Receptor Modulators (SERMs)

Tamoxifen and toremifene bind competitively to estrogen receptors, producing tissue-specific estrogen agonist or antagonist activities depending on local co-regulatory proteins:

• Breast Tissue: Acts as a potent ER antagonist, inhibiting estrogen-mediated gene transcription and tumor growth.
• Endometrial Tissue: Acts as a partial ER agonist, stimulating endometrial proliferation and increasing the long-term risk of endometrial hyperplasia and adenocarcinoma (2- to 3-fold elevated risk).
• Vascular System: Agonist activity increases hepatic synthesis of coagulation factors, elevating the risk of venous thromboembolism (VTE)—including deep vein thrombosis (DVT) and pulmonary embolism (PE)—as well as ischemic cerebrovascular events.
• Bone Mineral Density: Agonist activity in postmenopausal women preserves bone density; however, mild antagonist activity in premenopausal women can cause minor bone loss.

Clinical Pearl: Tamoxifen is a prodrug converted by the hepatic enzyme CYP2D6 into its primary active metabolite, endoxifen. Co-administration of potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, bupropion) significantly reduces endoxifen concentrations and impairs therapeutic efficacy. Selective serotonin reuptake inhibitors (SSRIs) with minimal CYP2D6 inhibition (e.g., venlafaxine, citalopram, escitalopram) are preferred for managing hot flashes.

B. Selective Estrogen Receptor Degraders (SERDs)

Fulvestrant (administered via monthly intramuscular injections) and elacestrant (an oral SERD indicated for ER+/HER2-, ESR1-mutated metastatic breast cancer) bind directly to the estrogen receptor, blocking estrogen binding, inhibiting receptor dimerization, and triggering rapid receptor degradation via the ubiquitin-proteasome pathway.

C. Aromatase Inhibitors (AIs)

Aromatase inhibitors block the enzyme CYP19A1 (aromatase), which catalyzes the final step in estrogen biosynthesis—converting adrenal androgens (androstenedione and testosterone) into estrogens (estrone and estradiol) in peripheral tissues (adipose tissue, liver, muscle).

• Non-Steroidal AIs (anastrozole, letrozole): Reversibly bind to the heme group of the cytochrome P450 unit of aromatase.
• Steroidal AIs (exemestane): Act as an irreversible, suicide substrate inhibitor of aromatase.

Menopausal Status Requirement: AIs do not inhibit ovarian estrogen production. Therefore, AIs are strictly indicated for postmenopausal women (or premenopausal women undergoing concurrent medical ovarian suppression with LHRH agonists). In premenopausal women with intact ovarian function, AI monotherapy induces a compensatory surge in pituitary gonadotropin release (FSH/LH), resulting in marked ovarian hyperstimulation.

---

2. Aromatase Inhibitor-Induced Bone Loss (AIBL) Protocol

Estrogen deprivation from AI therapy accelerates bone resorption, leading to Aromatase Inhibitor-Induced Bone Loss (AIBL) at a rate 2- to 3-fold higher than normal postmenopausal bone loss.

• Baseline Evaluation: Obtain baseline Dual-Energy X-Ray Absorptiometry (DEXA) scan measuring T-scores at the lumbar spine and hip prior to initiating AI therapy.
• Lifestyle Interventions: Recommend daily elemental calcium (1000–1200 mg/day via diet/supplements) plus Vitamin D3 (800–2000 IU/day), weight-bearing exercise, and smoking cessation.
• Pharmacologic Bone-Modifying Agents: Initiate bisphosphonate or RANKL inhibitor therapy based on DEXA T-score criteria:
  • T-score < -2.0 OR presence of ≥ 2 clinical risk factors for fracture (age > 65, T-score < -1.5, smoking, oral steroid use): Initiate intravenous zoledronic acid 4 mg IV every 6 months or subcutaneous denosumab 60 mg SQ every 6 months.
  • Zoledronic acid also demonstrates an adjuvant anti-cancer benefit, significantly reducing bone recurrence rates and improving overall survival in postmenopausal breast cancer patients.

---

3. Androgen Deprivation Therapy (ADT) in Prostate Malignancy

Prostate cancer growth is driven by testicular and adrenal androgens binding to the androgen receptor (AR). Androgen Deprivation Therapy (ADT) aims to achieve medical castration levels of serum testosterone (< 50 ng/dL, ideally < 20 ng/dL).

A. LHRH Agonists vs. GnRH Antagonists

• LHRH/GnRH Agonists (leuprolide, goserelin, triptorelin): Bind continuously to pituitary LHRH receptors. Initial administration induces a transient surge in LH and FSH release, causing a "tumor flare" (surge in serum testosterone lasting 1 to 2 weeks). In patients with extensive bone metastases, tumor flare can precipitate severe bone pain, spinal cord compression, or acute urinary obstruction. To prevent flare, co-administer a first-generation antiandrogen (bicalutamide 50 mg PO daily) starting 7 to 14 days prior to the first LHRH agonist injection and continue for 2 to 4 weeks.
• GnRH Antagonists (degarelix [subcutaneous], relugolix [oral]): Competitively block pituitary GnRH receptors immediately, producing rapid suppression of LH, FSH, and testosterone without inducing a tumor flare. Relugolix is associated with significantly lower major adverse cardiovascular events (MACE) compared to leuprolide.

B. Next-Generation Androgen Receptor Pathway Inhibitors (ARPIs)

In metastatic castration-sensitive and castration-resistant prostate cancer (mCRPC), novel ARPIs overcome persistent intra-tumoral androgen synthesis and receptor overexpression:

• Abiraterone Acetate: Potent, irreversible inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase), blocking androgen biosynthesis in the testes, adrenal glands, and prostate tumor tissue. Inhibiting CYP17 suppresses cortisol production, resulting in compensatory ACTH elevation and subsequent mineralocorticoid excess (hypertension, hypokalemia, fluid retention). Co-administration of low-dose prednisone (5 mg PO BID) is mandatory to suppress ACTH secretion and mitigate mineralocorticoid toxicities.
• Second-Generation AR Antagonists (enzalutamide, apalutamide, darolutamide): Direct competitive AR inhibitors that block androgen binding, inhibit AR nuclear translocation, and prevent AR binding to chromosomal DNA. Darolutamide exhibits low blood-brain barrier penetration, resulting in significantly lower central nervous system toxicities (fatigue, cognitive impairment, seizure risk) compared to enzalutamide or apalutamide.